Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations

被引:163
作者
Huang, Ningwu [1 ]
Agrawal, Vishal [1 ]
Giacomini, Kathleen M. [2 ]
Miller, Walter L. [1 ]
机构
[1] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA
关键词
cytochrome P450; drug metabolism; electron transfer; pharmacogenomics; steroidogenesis;
D O I
10.1073/pnas.0711621105
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
P450 oxidoreductase (POR) is an electron-donating flavoprotein required for the activity of all microsomal cytochrome P450 enzymes. We sequenced 5,655 bp of the POR gene in a representative population of 842 healthy unrelated individuals in four ethnic groups: 218 African Americans, 260 Caucasian Americans, 179 Chinese Americans, and 185 Mexican Americans. One hundred forty SNPs were detected, of which 43 were found in >= 1% of alleles. Twelve SNPs were in the POR promoter region. Fifteen of 32 exonic variations altered the FOR amino acid sequence;. 13 of these 15 are previously undescribed missense variations, We found eight indels, only one of which was in the coding region. A previously described variant, A503V, was found on 27.9% of all alleles with some ethnic predilection (19.1% in African Americans, 26.4% in Caucasian Americans, 36.7% Chinese Americans, an 31.0% in Mexican Americans). We built cDNA expression vectors for the 13 previously undescribed missense variants, expressed each protein lacking 27 N-terminal residues in Escherichia coli, and assayed the apparent K-m and V-max of each in four assays: reduction of cytochrome c, oxidation of NADPH, 17 alpha-hydroxylase activity of P450c17, and 17,20 lyase activity of P450c17. The catalytic activities of several missense mutants differed substantially in these assays, indicating that each POR mutant must be assayed separately with each potential target P450 enzyme. The activity of A503V was reduced to a modest but statistically significant degree in all four assays, suggesting that it may play an important role in interindividual variation in drug response.
引用
收藏
页码:1733 / 1738
页数:6
相关论文
共 39 条
  • [11] Pharmacogenomics: Translating functional genomics into rational therapeutics
    Evans, WE
    Relling, MV
    [J]. SCIENCE, 1999, 286 (5439) : 487 - 491
  • [12] Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome
    Flück, CE
    Tajima, T
    Pandey, AV
    Arlt, W
    Okuhara, K
    Verge, CF
    Jabs, EW
    Mendonça, BB
    Fujieda, K
    Miller, WL
    [J]. NATURE GENETICS, 2004, 36 (03) : 228 - 230
  • [13] Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: Molecular and clinical studies in 10 patients
    Fukami, M
    Horikawa, R
    Nagai, T
    Tanaka, T
    Naiki, Y
    Sato, N
    Okuyama, T
    Nakai, H
    Soneda, S
    Tachibana, K
    Matsuo, N
    Sato, S
    Homma, K
    Nishimura, G
    Hasegawa, T
    Ogata, T
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (01) : 414 - 426
  • [14] The Pharmacogenetics Research Network: From SNP discovery to clinical drug response
    Giacomini, K. M.
    Brett, C. M.
    Altman, R. B.
    Benowitz, N. L.
    Dolan, M. E.
    Flockhart, D. A.
    Johnson, J. A.
    Hayes, D. F.
    Klein, T.
    Krauss, R. M.
    Kroetz, D. L.
    McLeod, H. L.
    Nguyen, A. T.
    Ratain, M. J.
    Relling, M. V.
    Reus, V.
    Roden, D. M.
    Schaefer, C. A.
    Shuldiner, A. R.
    Skaar, T.
    Tantisira, K.
    Tyndale, R. F.
    Wang, L.
    Weinshilboum, R. M.
    Weiss, S. T.
    Zineh, I.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (03) : 328 - 345
  • [15] Cytochrome p450: What have we learned and what are the future issues?
    Guengerich, FP
    [J]. DRUG METABOLISM REVIEWS, 2004, 36 (02) : 159 - 197
  • [16] A variant in the cytochrome P450 oxidoreductase gene is associated with breast cancer risk in African Americans
    Haiman, Christopher A.
    Setiawan, V. Wendy
    Xia, Lucy Y.
    Le Marchand, Loic
    Ingles, Sue A.
    Ursin, Giske
    Press, Michael F.
    Bernstein, Leslie
    John, Esther M.
    Henderson, Brian E.
    [J]. CANCER RESEARCH, 2007, 67 (08) : 3565 - 3568
  • [17] Hartl D.L., 1997, PRINCIPLES POPULATIO
  • [18] Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase
    Henderson, CJ
    Otto, DME
    Carrie, D
    Magnuson, MA
    McLaren, AW
    Rosewell, I
    Wolf, CR
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (15) : 13480 - 13486
  • [19] HORECKER BL, 1950, J BIOL CHEM, V183, P593
  • [20] Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler Syndrome and disordered steroidogenesis
    Huang, NW
    Pandey, AV
    Agrawal, V
    Reardon, W
    Lapunzina, PD
    Mowat, D
    Jabs, EW
    Van Vliet, G
    Sack, J
    Flück, CE
    Miller, WL
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2005, 76 (05) : 729 - 749